surufatinib + camrelizumab + nab-paclitaxel + gemcitabine

This is a four-drug combination regimen under investigation as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The regimen includes: - **Surufatinib**: A small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1–3), fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF1R). It acts primarily as an antiangiogenic agent. - **Camrelizumab**: A monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance antitumor immune responses. - **Nab-paclitaxel**: An albumin-bound formulation of paclitaxel, which stabilizes microtubules and inhibits cell division. It is used widely in chemotherapy regimens for various cancers. - **Gemcitabine**: A nucleoside analog that inhibits DNA synthesis, commonly used in the treatment of pancreatic cancer. The combination aims to leverage antiangiogenic effects, immune checkpoint blockade, and cytotoxic chemotherapy to improve outcomes in patients with metastatic PDAC. This regimen is currently being evaluated in a multicenter Phase II/III clinical trial versus standard-of-care nab-paclitaxel plus gemcitabine[1][4][5].

Brand names

Abraxane (nab-paclitaxel)

Other names

none